PMID- 14565650
OWN - NLM
STAT- MEDLINE
DCOM- 20040323
LR  - 20220331
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 44
IP  - 9
DP  - 2003 Sep
TI  - Central venous catheter-related complications in patients with hematological 
      malignancies: a retrospective analysis of risk factors and prophylactic measures.
PG  - 1495-501
AB  - We retrospectively analyzed the incidence of thrombotic and infectious 
      complications in relation with the use of central venous catheters (CVCs), in a 
      series of patients with hematological malignancies and low platelet and leucocyte 
      counts. PATIENTS AND METHODS: 126 patients with hematological malignancies were 
      analyzed. A total of 207 CVCs were implanted: 137 centrally (CICCs) and 70 
      peripherally (PICCs). The median duration of the CVCs was 19 days for a total of 
      4051 catheter-days. Antithrombotic prophylaxis was unfractionated heparin (UFH), 
      2,500 IU daily by 24 h continuous infusion in 169 CVCs, low molecular weight 
      heparin (LMWH), 3,800 IU daily by single bolus intravenous injection (i.v.) in 21 
      and warfarin in one. No prophylaxis was given in 16 CVCs. Thrombotic 
      complications developed in 15.5% of the CVCs (7.9 events/1000 catheter days), and 
      the frequency of infectious complications was 10.6% (5.2 events/1000 catheter 
      days). On multivariate analysis thromboses were more frequent and earlier with 
      PICCs than CICCs (p = 0.0001), and in patients on UFH (16.6%) than in LMWH 
      prophylaxis (4.7%), but the last difference was not statistically significant. In 
      conclusions the incidence of thrombotic complications in our series was 
      comparable to that observed in non-thrombocytopenic patients and was 
      significantly higher in those carrying PICC than CICC (p = 0.0001). There were 
      fewer thrombotic events in the patients receiving i.v. LMWH prophylaxis than in 
      those receiving i.v. UFH. The use of anticoagulants was safe and not associated 
      with hemorrhages.
FAU - Cortelezzia, A
AU  - Cortelezzia A
AD  - Department of Hematology, IRCCS Maggiore Hospital and University of Milan, Milan, 
      Italy. cortelez@policlinico.mi.it
FAU - Fracchiolla, N S
AU  - Fracchiolla NS
FAU - Maisonneuve, P
AU  - Maisonneuve P
FAU - Moia, M
AU  - Moia M
FAU - Luchesini, C
AU  - Luchesini C
FAU - Ranzi, M L
AU  - Ranzi ML
FAU - Monni, P
AU  - Monni P
FAU - Pasquini, M C
AU  - Pasquini MC
FAU - Lambertenghi-Deliliers, G
AU  - Lambertenghi-Deliliers G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/therapeutic use
MH  - Bacteremia/epidemiology/*etiology/prevention & control
MH  - Catheterization, Central Venous/*adverse effects
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Fungemia/epidemiology/*etiology/prevention & control
MH  - Hematologic Neoplasms/complications/*therapy
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thrombocytopenia/complications
MH  - Thrombosis/epidemiology/*etiology/prevention & control
EDAT- 2003/10/21 05:00
MHDA- 2004/03/24 05:00
CRDT- 2003/10/21 05:00
PHST- 2003/10/21 05:00 [pubmed]
PHST- 2004/03/24 05:00 [medline]
PHST- 2003/10/21 05:00 [entrez]
AID - 10.3109/10428190309178770 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2003 Sep;44(9):1495-501. doi: 10.3109/10428190309178770.